Wednesday, April 22, 2026

5 wks

Moderna launches mRNA bird‑flu vaccine trial as preparedness ramps up (12) hot

5 wks

CMS delays Medicare GLP-1 pilot amid insurer skepticism (33) hot

CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback
Telehealth and clinics scale GLP‑1 access, delivery and monitoring
Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s

5 wks

UK enacts generational smoking ban law (12) hot

Parliament approves smoking ban for future generations
Explainers and advocacy for the Tobacco and Vapes Bill
Health context: cancer burden and treatment equity

In Detail Full day, Wednesday, April 22, 2026, Timezone: America/Chicago

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

Kristin Jensen / healthcaredive - A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.

AI Summary: Moderna has initiated a clinical trial of an mRNA vaccine targeting a potentially pandemic bird‑flu strain, joining global efforts to have a rapid‑response countermeasure ready. Regulators and public‑health experts hail the move as sensible pre‑emptive science—because nothing says “we planned for this” like testing the vaccine before the outbreak arrives.

#pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety #zoonoticdisease #avianinfluenza #infectiousdisease #clinicaltrials

Miriam Merad: Challenging Key Assumptions and Offering New Ways to Control mRNA Vaccine Activity

27 days / oncodaily

Host genetics and sex can steer flu toward greater virulence, mouse experiments reveal

4 wks / medicalxpress

NYC Health + Hospitals launches avian flu preparedness program

4 wks / beckershospitalreview / Ella Jeffries

Rethinking mRNA vaccines: Liver targeting can suppress immunity, while muscle boosts it

4 wks / medicalxpress

Local B cell immunity and durable memory after live-attenuated influenza intranasal vaccination of humans

4 wks / science / Hannah D. Stacey, Lucas Garin-Ortega, Paul G. Lopez, Parham Ramezani-Rad, Sydney I. Ramirez, Farhoud

Seasonal flu vaccines may reduce the severity of H5N1 bird flu infections

4 wks / medicalxpress

Animal-linked influenza D multiplies efficiently in human respiratory tissue, hinting at spillover

5 wks / medicalxpress

Pentagon drops flu vaccine requirement for US military

5 wks / medicalxpress

Africa’s moment for health security

5 wks / nature / Jean Kaseya

Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial

5 wks / healthcaredive / Kristin Jensen

If a bird flu pandemic starts, we may have an mRNA vaccine ready

5 wks / newscientist

Bird flu vaccine trial against potential pandemic strain begins

5 wks / bbc

CMS delays Part D GLP-1 model amid skepticism from insurers

fiercehealthcare - The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers.

AI Summary: Federal regulators have paused a Medicare Part D pilot to expand coverage for GLP‑1 weight‑loss drugs amid payer skepticism and implementation concerns. The delay reflects worries about cost, program design and insurer buy‑in, forcing policymakers to revisit the model while patients and providers wait for clarity on whether Medicare will shoulder these high‑price therapies.

#obesity #healthcare #pharmaceuticals #drugpricing #weightloss #governmentpolicy #healthcarefinance #diabetes #medicareadvantagenotlisted

CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback (4)
Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s (6)
Telehealth and clinics scale GLP‑1 access, delivery and monitoring (3)
All Other Stories

29 days / oncodaily

GLP-1 Drugs May Cut Risk of Heart Attack, Stroke, and Death by About 13 Percent

4 wks / discovermagazine

Omada signs on with Optum Rx's GLP-1 management program

4 wks / fiercehealthcare

Boston hospital links GLP-1 use to fewer ulcers

4 wks / beckershospitalreview / Ella Jeffries

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial

4 wks / medicalxpress

Court dismisses part of Lilly lawsuit against Empower, some claims can proceed

4 wks / endpoints / Shelby Livingston

FDA seeks to restrict compounding of key GLP-1s

4 wks / beckershospitalreview / Ella Jeffries

Lack of specifics on obesity pill sales hover over Lilly’s first quarter

4 wks / endpoints / Elizabeth Cairns

What to know about GLP-1 drugs for weight loss and health

4 wks / medicalxpress

Early data links Wegovy to risk of 'eye stroke' — here's what to know

4 wks / livescience

GLP-1 semaglutide tied to vision risk: Study

4 wks / beckershospitalreview / Ella Jeffries

One molecule, two effects: A new drug concept to treat obesity and type 2 diabetes

4 wks / medicalxpress

3 barriers to GLP-1 adherence — and how systems are overcoming them

4 wks / beckershospitalreview / Ella Jeffries

The push to expand access to emergency contraception

4 wks / fiercehealthcare / ,

Bariatric surgery is associated with greater long-term heart risk reduction than weight-loss medications

4 wks / medicalxpress

UK passes bill that will eventually ban cigarette purchases

abcnews - Parliament has passed a bill to make cigarettes inaccessible to future generations in the U.K. Children born after December 31, 2008, will never be able to buy cigarettes under the new Tobacco and Vapes Bill

AI Summary: The UK has passed legislation phasing out tobacco sales for younger generations, effectively banning cigarette purchases for people born after 2008. The law creates a rolling age‑based prohibition aimed at cutting smoking initiation and long‑term health harms, while stirring debate over enforcement, retail impact and the practicalities of turning childhood prevention into adult policy.

#healthcare #publichealth #governmentpolicy #behavioralhealth #healthdisparities #adolescenthealth